Corona Remedies Ltd
- Market Cap ₹ 6,495 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 43.3
- Book Value ₹
- Dividend Yield %
- ROCE 31.5 %
- ROE 27.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1,014 | 1,196 | |
| 859 | 956 | |
| Operating Profit | 156 | 241 |
| OPM % | 15% | 20% |
| 5 | 6 | |
| Interest | 14 | 11 |
| Depreciation | 28 | 37 |
| Profit before tax | 118 | 199 |
| Tax % | 24% | 25% |
| 90 | 149 | |
| EPS in Rs | ||
| Dividend Payout % | 25% | 30% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 61 | 61 |
| Reserves | 419 | 545 |
| 159 | 86 | |
| 191 | 237 | |
| Total Liabilities | 831 | 930 |
| 384 | 370 | |
| CWIP | 121 | 186 |
| Investments | 26 | 26 |
| 301 | 348 | |
| Total Assets | 831 | 930 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 157 | 190 | |
| -267 | -84 | |
| 99 | -107 | |
| Net Cash Flow | -11 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 36 | 36 |
| Inventory Days | 158 | 200 |
| Days Payable | 184 | 221 |
| Cash Conversion Cycle | 10 | 14 |
| Working Capital Days | -2 | 9 |
| ROCE % | 32% |
Documents
Annual reports
No data available.